法国成人中重度银屑病系统治疗指南:2025年更新
法国皮肤病学会银屑病研究组基于现有指南和近期文献制定新决策算法,更新成人中重度银屑病系统治疗策略。工作组推荐甲氨蝶呤、阿达木单抗或乌司奴单抗作为无有症状合并症患者的首选系统治疗,并涵盖长期管理、特殊类型及合并症/妊娠规划等推荐。
要点
- 无有症状合并症的成人中重度银屑病患者,首选甲氨蝶呤、阿达木单抗或乌司奴单抗。
- 指南提供斑块状银屑病和银屑病关节炎的更新治疗策略算法。
- 涵盖应答不足或低疾病活动度的长期管理及特殊类型、合并症、妊娠规划推荐。
核心结论
- 工作组推荐甲氨蝶呤、阿达木单抗或乌司奴单抗作为无有症状合并症银屑病患者的首选系统治疗。
研究设计与样本
- 法国皮肤病学会银屑病研究组制定,基于现有银屑病治疗指南和近期新系统治疗文献的全面综述。
主要发现
- 提出结合已有和新兴系统治疗的更新策略,适用于斑块状银屑病和银屑病关节炎患者。
- 包含应答不足或低疾病活动度的长期管理推荐,以及特定类型银屑病、合并症和妊娠规划患者的推荐。
关键数值与推荐
- 无有症状合并症患者首选系统治疗:甲氨蝶呤、阿达木单抗或乌司奴单抗。
临床怎么用
- 临床可依据更新算法为成人中重度银屑病选择系统治疗,并参考长期管理和特殊人群推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current French guidelines for the treatment of psoriasis date from 2019 and do not include the most up-to-date interventions. The Psoriasis Research Group of the French Society of Dermatology has developed new guidelines to provide updated decision-making algorithms for the systemic treatment of adult patients with moderate-to-severe psoriasis. The algorithms were created following a thorough review of existing psoriasis treatment guidelines and recent publications on new systemic therapies not included in previous recommendations. They propose updated treatment strategies that combine established and emerging systemic therapies for patients with plaque psoriasis and psoriatic arthritis. The working group recommends methotrexate, adalimumab or ustekinumab as the primary systemic treatment for patients with psoriasis without symptomatic comorbidities. Additionally, the guidelines include specific recommendations for long-term management in cases of insufficient response or low disease activity, as well as for treating specific types of psoriasis and managing patients with comorbid conditions or those planning a pregnancy.
引用
- Masson Regnault M, Brenaut E, Marniquet ME, et al. French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025. J Eur Acad Dermatol Venereol. 2025. PMID: 41469898. doi:10.1111/jdv.70263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。